<DOC>
	<DOC>NCT02014259</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of the trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body), safety and tolerability of oral semaglutide in subjects with various degrees of impaired renal function compared to subjects with normal renal function.</brief_summary>
	<brief_title>Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Male or female aged 1885 years (both inclusive) at the time of signing inform consent Subject with normal renal function or renal impairment (mild, moderate, severe or endstage renal disease requiring dialysis) For subject with normal renal function: good general health (as judged by the investigator) Body mass index (BMI) 18.540.0 kg/m^2 (both inclusive) Female who is pregnant, breastfeeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive methods History of Crohn's disease, ulcerative colitis, or other inflammatory bowel disease Uncontrolled hypertension (defined as systolic blood pressure above or equal to 180 mmHg and/or diastolic blood pressure above or equal to 100 mmHg) Any blood draw or donation of blood or plasma in excess of 400 mL within the 3 months preceding the screening visit (Visit 2) History of significant drug abuse, or a positive drug test at the screening visit (Visit 2)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>